Bitcoin has historically dropped in the fourth quarter during U.S. midterm election years but gained significantly one year after each vote, according to Joe Consorti's analysis. Despite short-term losses of up to 43.5% post-election, Bitcoin was the best-performing major asset in the year following the 2014, 2018, and 2022 midterms. Current market pressures include recent price declines, high investor acquisition costs, ETF outflows, and macroeconomic concerns like central bank tightening and AI investment returns. Election results may cause short-term volatility, but Bitcoin's long-term trend shows strong gains and new records within two and a half years after each election.
Bitcoin's price trends around U.S. midterm elections provide context for readers. For those following cryptocurrency markets, here is Pluang's snapshot: out of 50 major cryptocurrencies, 45 rose and 4 fell today. Notable moves include BAT at Rp2.532 with a 10.32% gain, EOS at Rp12.649 up 8.13%, and CAKE at Rp36.489 rising 6.99%, as of Nov 05, 2026 00:31 WIB.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
